283 related articles for article (PubMed ID: 27720129)
21. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
23. Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study.
Ghosh S; Rao PB; Kumar PR; Manam S
Asian Pac J Cancer Prev; 2015; 16(16):7309-13. PubMed ID: 26514529
[TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
25. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
[TBL] [Abstract][Full Text] [Related]
26. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
27. Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: outcomes from a single-institution series.
Johnston M; Guo L; Back M; Guminski A; Lee A; Hanna C; Veivers D; Wignall A; Eade T
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):356-63. PubMed ID: 23721147
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
[TBL] [Abstract][Full Text] [Related]
29. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study.
Welsh L; Panek R; McQuaid D; Dunlop A; Schmidt M; Riddell A; Koh DM; Doran S; Murray I; Du Y; Chua S; Hansen V; Wong KH; Dean J; Gulliford S; Bhide S; Leach MO; Nutting C; Harrington K; Newbold K
Radiat Oncol; 2015 May; 10():112. PubMed ID: 25971451
[TBL] [Abstract][Full Text] [Related]
30. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
Sakashita T; Homma A; Oridate N; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Auris Nasus Larynx; 2013 Apr; 40(2):211-5. PubMed ID: 22867524
[TBL] [Abstract][Full Text] [Related]
31. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
33. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
[TBL] [Abstract][Full Text] [Related]
34. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
35. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
36. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.
Trifiletti DM; Smith A; Mitra N; Grover S; Lukens JN; Cohen RB; Read P; Mendenhall WM; Lin A; Swisher-McClure S
J Clin Oncol; 2017 May; 35(14):1550-1560. PubMed ID: 28475848
[TBL] [Abstract][Full Text] [Related]
37. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
38. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
40. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]